PLCG2 missense and nonsense mutations are reported in 2% of all cancers (https://www.mycancergenome.org/content/gene/plcg2) as in colon cancer, lung cancer, prostate cancer, endometrial carcinoma, and cutaneous melanoma, as well as in ibrutinib-resistant chronic lymphocytic leukemia patients (73). This evidence concerns the gene PLCG2 and prostate cancer.